Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 2.71 EUR 0.37%
Market Cap: 212.9m EUR

Intrinsic Value

ORY's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one ORY stock under the Base Case scenario is 1.17 EUR. Compared to the current market price of 2.71 EUR, Oryzon Genomics SA is Overvalued by 57%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ORY Intrinsic Value
1.17 EUR
Overvaluation 57%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Oryzon Genomics SA

Valuation History Unavailable

Historical valuation for ORY cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Oryzon Genomics SA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Oryzon Genomics SA

Current Assets 5.4m
Cash & Short-Term Investments 3.8m
Receivables 1.6m
Other Current Assets 13.6k
Non-Current Assets 101.9m
Long-Term Investments 125.5k
PP&E 341.4k
Intangibles 99m
Other Non-Current Assets 2.4m
Efficiency

Free Cash Flow Analysis
Oryzon Genomics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Oryzon Genomics SA

Revenue
0 EUR
Cost of Revenue
-1.3m EUR
Gross Profit
-1.3m EUR
Operating Expenses
-3.6m EUR
Operating Income
-4.9m EUR
Other Expenses
652k EUR
Net Income
-4.2m EUR
Fundamental Scores

ORY Profitability Score
Profitability Due Diligence

Oryzon Genomics SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

36/100
Profitability
Score

Oryzon Genomics SA's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

ORY Solvency Score
Solvency Due Diligence

Oryzon Genomics SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Positive Net Debt
57/100
Solvency
Score

Oryzon Genomics SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ORY Price Targets Summary
Oryzon Genomics SA

Wall Street analysts forecast ORY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ORY is 7.55 EUR with a low forecast of 4.04 EUR and a high forecast of 12.6 EUR.

Lowest
Price Target
4.04 EUR
49% Upside
Average
Price Target
7.55 EUR
179% Upside
Highest
Price Target
12.6 EUR
365% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Oryzon Genomics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for ORY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one ORY stock?

The intrinsic value of one ORY stock under the Base Case scenario is 1.17 EUR.

Is ORY stock undervalued or overvalued?

Compared to the current market price of 2.71 EUR, Oryzon Genomics SA is Overvalued by 57%.

Back to Top